The aim of the study was to evaluate the relationship between clinical and pathological factors and survival in patients with double negative HER2-overexpressing carcinoma and triple negative carcinoma. One hundred and sixty-one (161) patients diagnosed with breast cancer negative for estrogen receptor (ER) and progesterone receptor (PR) were included. Of the total, 58 patients had double negative HER2-overexpressing (ER/PR-negative and HER2-positive) and 103 had triple negative (ER-negative, PR-negative and HER2-negative). ER and PR expression was assessed through immunohistochemistry (IHC) and HER2 expression was measured by immunohistochemistry and Fluorescent in situ Hybridization (FISH) analysis in tissue microarray. More than 80% had stages II and III disease and histologic grade III and nuclear grade 3. Patients with triple negative breast carcinoma had undifferentiated histologic types in 11% of cases and vascular invasion in 14.5%. Both groups had more than 50% visceral metastases. HER2 expression (p= 0.42) and vascular invasion (p= 0.05) did not interfere with survival. Survival of patients with Stages I-II disease was significantly longer than in those with Stage III disease both for double negative HER2-overexpressing carcinomas (p< 0.0001) and triple negative carcinomas (p= 0.03). The study shows that hormone receptor-negative breast carcinomas were undifferentiated and diagnosed at advanced stages and that HER2 expression was not associated with overall survival. © 2012 Elsevier GmbH.1152120127(2011) Coordenação nacional de prevenção e vigilância. Estimativa 2012: incidência de câncer no Brasil (online only), , http://www.inca.gov.br/estimativa/2012/versaofinal.pdf, Instituto Nacional do Câncer.Ministério da Saúde, INCA, Rio de Janeiro, Available online at: [last accessed 30.11.11]Bae, S.Y., Lee, S.K., Koo, M.Y., Hur, S.M., Choi, M., Cho, D.H., The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients (2011) Breast Cancer Res Treat, 126, pp. 471-478Brown, M., Tsodikov, A., Bauer, K.R., Parise, C.A., Caggiano, V., The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative invasive breast cancer (2008) Cancer, 15, pp. 737-747Burstein, H.J., The distinctive nature of HER2-positive breast cancers (2005) N Engl J Med, 353, pp. 1652-1654Cheang, M., Chia, S.K., Tu, S., Jiang, S., Shepherd, L.E., Pritchard, K.I., Anthracyclines in basal breast cancer: the NCICCTG trial MA5 comparing adjuvant CMF to CEF (2009) J Clin Oncol, 27 (15 S)Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A.M., Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers (2008) J Clin Oncol, 26, pp. 5697-5704Coleoni, M., Cole, B.F., Viale, G., Regan, M.M., Price, K.N., Maiorano, E., Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer (2010) J Clin Oncol, 28, pp. 2966-2973Dawood, S., Broglio, K., Esteva, F.J., Yang, W., Kau, S.W., Islam, R., Survival among women with triple receptor-negative breast cancer and brain metastases (2009) Ann Oncol, 20, pp. 621-627de Mascarel, I., MacGrogan, G., Debled, M., Sierankowski, G., Brouste, V., Mathoulin-Pélissier, S., D2-40 in breast cancer: should we detect more vascular emboli? (2009) Mod Pathol, 22, pp. 216-222Dowsett, M., Cooke, T., Ellis, I., Gullick, W.J., Gusterson, B., Mallon, E., Assessment of HER2 status in breast cancer: why, when and how? (2000) Eur J Cancer, 36, pp. 170-176Dunnwald, L.K., Rossing, M.A., Li, C., Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients (2007) Breast Cancer Res, 9, pp. R6Ejlertsen, B., Jensen, M.B., Rank, F., Rasmussen, B.B., Christiansen, P., Kroman, N., Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer (2009) J Natl Cancer Inst, 101, pp. 729-735Falo, C., Moreno, A., Varela, M., Lloveras, B., Figueras, A., Escobedo, A., Her-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy (2007) J Cancer Res Clin Oncol, 133, pp. 423-429Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], , http://globocan.iarc.fr, International Agency for Research on Cancer, Lyon, France, Available from: [accessed 30.11.11]Gaedcke, J., Traub, F., Milde, S., Wilkens, L., Stan, A., Ostertag, H., Predominance of the basal type and HER-2/neu type in brain metastases from breast cancer (2007) Mod Pathol, 20, pp. 864-870Goldhirsch, A., Ingle, J.N., Gelber, R.D., Coates, A.S., Thürlimann, B., Senn, H.J., Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 (2009) Ann Oncol, 20, pp. 1319-1329Grann, V.R., Troxel, A.B., Zojwalla, N.J., Jacobson, J.S., Hershman, D., Neugut, A.I., Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma (2005) Cancer, 103, pp. 2241-2251Gruvberger, S., Ringnér, M., Chen, Y., Panavally, S., Saal, L.H., Borg, A., Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns (2001) Cancer Res, 61, pp. 5979-5984Hammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) (2010) Arch Pathol Lab Med, 134, pp. e48-e72Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer (2007) J Clin Oncol, 25, pp. 5287-5312Hewitt, S.C., Korach, K.S., Estrogen receptors: structure, mechanisms and function (2002) Rev Endocr Metab Disord, 3, pp. 193-200Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., The molecular portraits of breast tumors are conserved acrossmicroarray platforms (2006) BMC Genomics, 7, p. 96Iwase, H., Kurebayashi, J., Tsuda, H., Ohta, T., Kurosumi, M., Miyamoto, K., Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society (2010) Breast Cancer, 17, pp. 118-124Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M., Voduc, D., Speers, C., Metastatic behavior of breast cancer subtypes (2010) J Clin Oncol, 28, pp. 3271-3277Korsching, E., Jeffrey, S.S., Meinerz, W., Decker, T., Boecker, W., Buerger, H., Basal carcinoma of the breast revisited: an old entity with new interpretations (2008) J Clin Pathol, 61, pp. 553-560Lehmann-Che, J., André, F., Desmedt, C., Mazouni, C., Giacchetti, S., Turpin, E., Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers (2010) Oncologist, 15, pp. 246-252Leyland-Jones, B., Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases (2009) J Clin Oncol, 27, pp. 5278-5286Middleton, L.P., Price, K.M., Puiq, P., Hevdon, L.J., Tarco, E., Sneige, N., Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases (2009) Arch Pathol Lab Med, 133, pp. 775-780Minn, A.J., Gupta, G.P., Padua, D., Bos, P., Nguyen, D.X., Nuyten, D., Lung metastasis genes couple breast tumor size and metastatic spread (2007) Proc Natl Acad Sci USA, 104, pp. 6740-6745Pelekanou, V., Leclercq, G., Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis (2011) Int J Devel Biol, 55, pp. 869-878Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.H., Davidson, N.E., Geyer, C.E., Four-year of Trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31 (2011) J Clin Oncol, 29, pp. 3366-3373Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Molecular portraits of human breast tumors (2000) Nature, 406, pp. 747-752Putti, T., El-Rehim, D.M., Rakha, E.A., Paish, C.E., Lee, A.H.S., Pinder, S.E., Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis (2005) Mod Pathol, 18, pp. 26-35Ragage, F., Debled, M., MacGrogan, G., Brouste, V., Desrousseaux, M., Soubeyran, I., Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? (2010) Cancer, 116, pp. 3093-3101Rakha, E., Martin, S., Lee, A., Morgan, D., Pharoah, P., Hodi, A., The prognostic significance of lymphovascular invasion in invasive breast carcinoma (2011) Cancer, (DECEMBER). , [Epub ahead of print]Rastogi, P., Anderson, S.J., Bear, H.D., Geyer, C.E., Kahlenberg, M.S., Robidoux, A., Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 (2008) J Clin Oncol, 26, pp. 778-785Reis-Filho, J.S., Milanezi, F., Steele, D., Savage, K., Simpson, P.T., Nesland, J.M., Metaplastic breast carcinomas are basal-like tumours (2006) Histopathology, 49, pp. 10-21Rodríguez-Pinilla, S.M., Rodríguez-Gil, Y., Moreno-Bueno, G., Sarrió, D., Martín-Guijarro Mdel, C., Hernandez, L., Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study (2007) Am J Surg Pathol, 31, pp. 501-508Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene (1987) Science, 235, pp. 177-182Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Adjuvant trastuzumab in HER2-positive breast cancer (2011) N Engl J Med, 365, pp. 1273-1283Sobin, L.H., Gospodarowics, M.K., Wittekind, C., (2009) TNM classification of malignant tumours, , Wiley, NJSørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (2001) Proc Natl Acad Sci USA, 98, pp. 10869-10874Tavassoli, F.A., Devilee, P., (2003) World Health Organization classification of tumours. pathology and genetics of tumours of the breast and female genital organs, , IARC Press, LyonWeigelt, B., Horlings, H.M., Kreike, B., Hayes, M.M., Hauptmann, M., Wessels, L.F., Refinement of breast cancer classification by molecular characterization of histological special types (2008) J Pathol, 216, pp. 141-150